Friday, 19 April 2024

 

 

LATEST NEWS Vigilance Bureau nabs ASI for accepting Rs 15,000 bribe J&K at threshold of mega development under PM Modi’s leadership : Surjeet Singh Slathia Breaking: Punjab School Education Board (PSEB) 10th Result 2024 Declared Shayar Movie Review: A Magical Journey Through The World Of Shayari 6 Top Kavita Radheshyam Web Series To Watch | 5 Dariya News Varun Sood Net Worth 2024: Uncovering the Wealth of A Multi Talented Star | 5 Dariya News Punjab Congress Kickstart Election Campaign From Sangrur A Night of Stars And Striking Performances inside the Grand Premiere of 'Shayar' Tsunami of AAP in Bharuch - Massive turnout in Bhagwant Mann's 'Jan Ashirwad Yatra' in Gujarat Meeting of all BJP district in-charges, presidents, general secretaries, morcha and mañdal presidents and general secretaries held in BJP office Gurjit Singh Aujla bowed down to Shri Harmandir Sahib and Sri Durgiana temple Birla Open Minds Joins Forces with Rohit Sharma Cricket Academy CricKingdom to Elevate Cricket Programs within their schools ''PEC had always been Jaspal Ji's Second Mother'': Savita Bhatti The Ultimate Guide to Sustainable Kitchen Cleaning Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024 SOMANY MAX Glazed Vitrified Tiles (GVT) - A New Standard in the Tiles Vertical DC conducts surprise inspection in Gill Road grain market Ensure strict compliance of 'Safe School Vahan Policy' for safety of students or be ready to face action - DC to school heads Administration to make all-out efforts to wipe out child begging Sanjay Tandon Emphasizes Senior Citizens' Crucial Role in Society Punjab Police Solves Murder Case Of VHP Leader Within 72 Hours; Two Assailants Held

 

Experimental stem cell therapy shows promise for epilepsy patients

Health, Study, New York, Research, Researchers, World News,  Stem Cell Therapy, Neurona Therapeutics, NRTX-1001, Oregon Health & Science University
Listen to this article

Web Admin

Web Admin

5 Dariya News

New York , 19 Jun 2023

An experimental stem cell therapy has reduced seizure frequency by almost 95 per cent in the first two epilepsy patients, according to early results of a trial. Developed by San Francisco-based biotech Neurona Therapeutics, the single dose therapy, called NRTX-1001, involves lab-grown neurons which are injected in the patients to silence the seizure activity in the epileptic region of the brain.

The regenerative neural cell therapy, NRTX-1001, was derived from human pluripotent stem cells. The preliminary data demonstrate promising reduction (90 per cent) in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. In addition, neuropsychological testing suggests an improvement in memory after NRTX-1001 administration.

"Although our clinical investigation is ongoing in additional patients, it is gratifying to witness the first two patients achieving seizure relief without additional cognitive impairment to date," said Cory Nicholas, the CEO of Neurona Therapeutics, in a statement.

"We are hopeful that these improvements will continue in the ongoing trial," he added. The early findings were presented at the recently held International Society for Stem Cell Research's annual meeting in Boston, US.

The two patients had a history of significant monthly seizure activity that was not controlled by anti-seizure medications. The first patient, treated at SUNY Upstate Medical University, had a seven-year history of seizures, and in the six months prior to the administration of NRTX-1001 experienced an average of 32 seizures per month.

The second patient treated in the trial, at the Oregon Health & Science University, had a nine-year history of seizures and averaged 14 seizures per month in the six months prior to treatment. Both patients continue to report reduced overall seizure counts of more than 90 per cent at one year and seven-months post NRTX-1001 administration, respectively. 

No serious adverse events have been reported. "Patient-one has reached the one-year post treatment endpoint and has achieved more than 95 per cent overall monthly seizure reduction, including elimination of all seizure events since the seventh month post-administration of NRTX-1001," said David Blum, Neurona's chief medical officer, in the statement.

"In addition, this patient has shown improved memory performance on cognitive tests," he added.

 

Tags: Health , Study , New York , Research , Researchers , World News , Stem Cell Therapy , Neurona Therapeutics , NRTX-1001 , Oregon Health & Science University

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2024 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD